Imaging-Based Immunoassay Reducing Non-Specific Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current immunoassays face challenges such as non-specific binding, reagent variability, and limited sensitivity due to the use of microparticles as solid supports, which can lead to false results and require extensive calibration and reagent optimization, and lack of record-keeping for assay data.

Innovation Solution

A method involving a reaction mixture with a sample, capture antibodies attached to microparticles, and fluorescently labeled detection antibodies, where white light and fluorescence images are acquired to determine the location and intensity of complexes, allowing for the calculation of antigen concentration by selecting regions of interest and omitting pixels with high variance, thereby improving sensitivity and reducing reagent use.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If microparticles are used as solid support in immunoassays, then separation of bound and unbound conjugate is simplified, but non-specific binding and reagent variability increase leading to false results

Engineering Contradiction:
Improveseparation of bound and unbound conjugateVSAvoidassay accuracy
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent extracts the solid support (microparticles) from the final measurement step. Instead of measuring signal from microparticles with bound conjugate, the conjugate is transferred to a flat surface for imaging, eliminating microparticle-related non-specific binding and variability while preserving the ease of separation that microparticles provide during the binding process.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The assay process is segmented into distinct phases: binding phase using microparticles for easy separation, then transfer phase to flat surface for measurement. This segmentation allows each phase to optimize for its specific function without the drawbacks of using microparticles during measurement.

Inventive Principle:
Principle #1Segmentation

2Device complexity

If conventional immunoassays measure light signal from total volume, then the procedure is simple, but sensitivity is limited due to non-specific binding and background noise

Engineering Contradiction:
Improvemeasurement procedureVSAvoidsensitivity
Core Design Contradiction:
Device complexityVSMeasurement precision

Solution Approach 1:

The patent replaces the conventional bulk optical measurement system with an imaging system that captures spatial information. Instead of measuring total light from the entire reaction volume, the system images individual complexes on a flat surface, allowing exclusion of background areas and significantly improving sensitivity while maintaining procedural simplicity.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The measurement approach shifts from global (total volume signal) to local (individual complex signal). By imaging and analyzing only regions containing specific antigen-conjugate complexes, the method eliminates background noise from non-specific binding while preserving signal from specific binding events.

Inventive Principle:
Principle #3Local quality

3Reliability

If extensive calibration and reagent optimization are performed to reduce non-specific binding, then assay reliability improves, but time and resource consumption increase

Engineering Contradiction:
Improveassay reliabilityVSAvoidcalibration and optimization time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

By extracting the measurement from microparticles to a flat surface, the patent eliminates the primary source of non-specific binding and reagent variability. This reduces the need for extensive calibration and reagent optimization, as the system inherently produces more reliable results with less background noise.

Inventive Principle:
Principle #2Taking out (Extraction)

4Quantity of substance

If conventional immunoassays use total volume measurement, then reagent consumption is high, but the method is well-established and simple

Engineering Contradiction:
Improvereagent consumptionVSAvoidmeasurement method
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent transitions from three-dimensional bulk measurement to two-dimensional surface imaging. By concentrating complexes on a flat surface and imaging them, the method reduces the effective measurement volume, allowing lower reagent consumption while maintaining detection capability. The added dimension of spatial resolution compensates for the reduced reagent volume.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enhances the sensitivity and accuracy of immunoassays by eliminating non-specific binding and aggregation, reducing reagent consumption, and enabling real-time quality control, while allowing for the storage and review of assay data for future analysis.

Implementation Method 1

A conjugate, which comprises a second antibody having a label attached thereto, is introduced to the reaction mixture and specifically binds to the antigen

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentEP3527987B1Spatially resolved ligand-receptor binding assays
Publication Date: 2023.08.23 ABBOTT LAB INC
  • EP3527987B1 patent drawingFigure 1
  • EP3527987B1 patent drawingFigure 2
  • EP3527987B1 patent drawingFigure 3

AI summary

A method for determining the concentration of an antigen in a sample comprising the steps of: (a) combining in a reaction mixture (i) a sample suspected of containing an antigen, (ii) a capture antibody attached to a microparticle, which capture antibody specifically binds to the antigen, and (iii) a fluorescently labeled detection antibody which specifically binds to the antigen, and allowing formation of a complex comprising the microparticle attached to the capture antibody, the antigen, and the detection antibody; (b) acquiring a white light image of the reaction mixture in order to determine the location of the microparticle in the reaction of step (a) and a fluorescence image of the reaction mixture in order to determine the location of the fluorescently labeled detection antibody in the reaction of step (a); (c) selecting at least one region of interest from the images acquired in step (b), wherein the at least one region of interest is a region from which light signals emanate from the complex formed in step (a); (d) selecting pixels in the at least one region of interest for analysis; (e) calculating and recording the average and variance of the counts per pixel for the pixels selected in step (d), wherein the counts per pixel is the number of photons counted per pixel per unit of time; (f) omitting pixels that have counts greater or less than a specified variance; (g) calculating average counts per pixel of the remaining pixels; and (h) determining the concentration of the antigen from the data in step (g).